Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…ignaling was enriched in these inflammatory monocytes following leuprolide treatment in both patients and mice. Further, we identified an …
…ects. These findings suggest its potential for the treatment of solid tumors in humans.…
…K Assay; and 21 patients with advanced ccRCC being treated with ipilimumab and nivolumab (ipi+nivo), assessed pre-treatment and prior to c…
…57BL/6) mice and treated 7d later with equivalent virus dose of C027 (C134+IL27) or parent virus (C134) or vehicle control. To asses…
…, Cohen S. Genetic factors associated with clinical response in melanoma patients treated with talimogene laherparapvec: a single-instit…
…dscape of ER+ BC. By converting ‘cold’ tumours into ‘hot’ ones, VacV000 holds promise for synergistic use with other immunotherapies.Ac…
…ntitumor activity. While TCEs are effective in the treatment of hematological malignancies, achieving clinical antitumor activity in solid tumors has been…
…D-1 and CTLA-4, suggesting that tumor-secreted VEGF may amplify CT111 activity within the TME. These findings support clinical develo…
…n agonists as a therapeutic intervention in elderly people with depression.Methods and analysis This systematic review protocol was regist…
…D) SCS intake duration was 23.5 (21.3) and 34.9 (26.4) days for dupilumab and placebo, respectively; antibiotic intake duration was 17.8 …
…dupilumab n=573; placebo n=562) had baseline BEC ≥300 cells/µL. Dupilumab reduced annualized exacerbation rates vs placebo by 36.9% (BEC …
…zed to receive one of three treatment strategies: benralizumab, prednisolone, or a combination of both. IOS parameters, including inspirator…